DEF: Actelis Seeks Shareholder Nod for $30M Equity Line

Sentiment:

Proxy Statement


Actelis Networks, Inc. will hold a special meeting on January 29, 2026, to seek shareholder approval for the issuance of common stock under a $30 million ELOC Purchase Agreement with White Lion Capital, LLC.

Capital raiseThe company entered into a Common Stock Purchase Agreement with White Lion Capital, LLC, providing the right to sell up to $30,000,000 of common stock.This agreement functions as an Equity Line of Credit (ELOC), allowing the company to raise capital on an 'as-needed' basis.As consideration for White Lion's commitment, Actelis issued 284,091 shares of common stock.Shareholder approval is being sought to enable the company to issue shares beyond the 19.99% cap imposed by Nasdaq Listing Rule 5635(d), which is crucial for fully utilizing the $30 million facility.

Summary

  • A special meeting of stockholders will be held on January 29, 2026, at 10:00 a.m. (Eastern Standard Time) at the company's offices in Petach Tikva, Israel.
  • The primary proposal is to authorize, in accordance with Nasdaq Listing Rule 5635(d), the issuance of shares of common stock pursuant to the company's ELOC Purchase Agreement.
  • The ELOC Purchase Agreement, effective October 1, 2025, grants Actelis the right, but not the obligation, to require White Lion Capital, LLC to purchase up to $30,000,000 in aggregate gross purchase price of newly issued common stock.
  • Shareholder approval is required for issuances exceeding 19.99% of the common stock outstanding prior to the agreement's execution or if sales are deemed to be for less than the Nasdaq Minimum Price.
  • If shareholder approval is not obtained, the company is obligated to call additional special meetings every 90 days thereafter, for a total period of 360 days, until approval is secured.
  • As consideration for White Lion's irrevocable commitment, Actelis issued 284,091 shares of common stock to White Lion.
  • The Board of Directors recommends a 'FOR' vote for Proposal No. 1 (ELOC Issuance) and Proposal No. 2 (Adjournment).

Sentiment

Score: 6

Explanation: The filing outlines a strategic move to secure significant financial flexibility through an ELOC, which is positive for the company's long-term operational stability and growth potential. However, this comes with the inherent negative of substantial potential dilution for existing shareholders and potential stock price volatility. The board's strong recommendation for approval indicates the strategic importance of this financing.

Positives

  • The ELOC Purchase Agreement provides Actelis with the right, but not the obligation, to raise up to $30,000,000 in capital, offering significant financial flexibility.
  • The agreement extends until October 1, 2028, providing a long-term financing option for the company's business plans.
  • The company has already secured White Lion Capital's commitment, for which 284,091 Commitment Shares were issued.

Negatives

  • The issuance of shares under the ELOC Purchase Agreement will have a dilutive effect on existing stockholders, impacting their voting power and economic rights.
  • Future sales of shares to White Lion could adversely affect prevailing market prices of the common stock, potentially leading to a decline in stock price or greater price volatility.
  • The company is obligated to pay liquidated damages to White Lion if it fails to call the Special Meeting within 120 days of October 1, 2025.
  • If shareholder approval is not obtained, the company is obligated to call additional Special Meetings every 90 days for 360 days, incurring additional costs and administrative burden.
  • The purchase price for shares sold to White Lion is at a discount (e.g., 97.5% of the lower of VWAP or closing price for Regular Purchases, or lowest traded price/99% of lowest traded price for Rapid Purchases).

Risks

  • Dilution of existing stockholders' voting power and economic rights due to the issuance of new common stock.
  • Potential decline in stock price or increased price volatility resulting from future share issuances and sales to White Lion Capital, LLC.
  • Obligation to pay liquidated damages if the special meeting for shareholder approval is not called within the specified timeframe.
  • Requirement to call multiple special meetings if initial shareholder approval for the ELOC issuance is not obtained.

Future Outlook

The ELOC Purchase Agreement is expected to provide Actelis Networks with significant financial flexibility, enabling the company to implement its business plans and potentially generate value for stockholders by ensuring access to capital for future needs.

Management Comments

  • "BECAUSE OF THE SIGNIFICANCE OF THESE PROPOSALS TO THE COMPANY AND ITS STOCKHOLDERS, IT IS VITAL THAT EVERY STOCKHOLDER VOTES AT THE SPECIAL MEETING IN PERSON OR BY PROXY."
  • "For the reasons set forth in the Proxy Statement, your Board of Directors recommends a vote FOR Proposal Nos. 1 and 2."
  • "The Board and the management of the Company believe that the potential to use the ELOC Purchase Agreement would provide the Company flexibility in how it implements its business plans and ultimately generates value for its stockholders."

Industry Context

The use of an Equity Line of Credit (ELOC) is a common financing strategy for publicly traded companies, particularly those with smaller market capitalizations or in growth phases, seeking flexible access to capital without the immediate burden of traditional debt or a large, upfront equity offering. This mechanism allows companies to draw funds as needed, providing liquidity and operational flexibility, though it typically involves share issuances at a discount and carries the risk of dilution for existing shareholders.

Comparison to Industry Standards

  • The structure of the ELOC, allowing the company to draw funds as needed up to $30 million, is a standard flexible financing tool often employed by growth-oriented companies in the technology or telecommunications sector, similar to those used by peers requiring intermittent capital injections.
  • The requirement for shareholder approval for issuances exceeding 19.99% of outstanding shares aligns with Nasdaq Listing Rule 5635(d), a common corporate governance benchmark designed to protect shareholders from excessive dilution without their explicit consent, consistent with practices across U.S. exchanges.
  • The pricing mechanism, involving discounts to VWAP or lowest traded prices, is typical for ELOC agreements, reflecting the investor's commitment and the liquidity provided, comparable to terms seen in similar agreements with institutional investors like Lincoln Park Capital or Aspire Capital.

Corporate Governance

Change TypeDescriptionEffective DateImpact Assessment
Shareholder Approval RequirementSeeking shareholder approval for the issuance of common stock under the ELOC Purchase Agreement beyond the Nasdaq 19.99% cap (Rule 5635(d)).January 29, 2026 (if approved)Ensures compliance with Nasdaq listing rules and provides transparency to shareholders regarding potential dilution from future capital raises, upholding corporate governance standards.

Stakeholder Impact

  • Shareholders: Face potential significant dilution of voting power and economic rights, and possible stock price volatility due to future share issuances.
  • Company: Gains enhanced financial flexibility and access to up to $30,000,000 in capital, which is crucial for funding business plans and operations.
  • White Lion Capital, LLC: Benefits from the opportunity to purchase company stock at a discount, potentially realizing gains from future stock price appreciation.

Next Steps

  • Stockholders are urged to vote on Proposal No. 1 (ELOC Issuance) and Proposal No. 2 (Adjournment) at the Special Meeting on January 29, 2026.
  • If Proposal No. 1 is not approved, the company is obligated to call additional Special Meetings every 90 days for 360 days until approval is obtained.
  • Upon shareholder approval, the company may issue shares to White Lion Capital, LLC, under the ELOC Purchase Agreement until October 1, 2028, subject to the terms and conditions.

Key Dates

DateDescription
October 1, 2025Effective date of the Common Stock Purchase Agreement with White Lion Capital, LLC.
October 2, 2025Date of filing of Current Report on Form 8-K with the SEC regarding the ELOC Purchase Agreement.
December 31, 2025Record Date for stockholders entitled to receive notice of, attend, and vote at the Special Meeting.
January 7, 2026Approximate date for mailing of the Proxy Statement and Proxy Card to stockholders.
January 28, 2026Deadline for electronic or telephonic proxy votes (11:59 PM EST).
January 29, 2026Date of the Special Meeting of Stockholders at 10:00 a.m. (Eastern Standard Time).
October 1, 2028End of the Commitment Period for the ELOC Purchase Agreement, unless the company has exercised its right in full to sell shares prior to this date.

Recommendation

hold

The ELOC Purchase Agreement provides Actelis Networks with a crucial source of flexible capital, up to $30 million, which is vital for supporting its business plans and ensuring operational continuity. This access to funding is a significant positive for the company's strategic flexibility. However, the mechanism inherently involves the issuance of new common stock at a discount to market prices, leading to substantial dilution for existing shareholders. This dilution, coupled with the potential for increased stock price volatility as White Lion sells shares into the market, presents a notable downside risk. Given the dual nature of enhanced financial stability versus significant dilution, a 'hold' recommendation is appropriate. Investors should closely monitor the company's utilization of this capital, the pace of share issuances, and the resulting impact on per-share metrics and overall stock performance. The board's strong recommendation for approval underscores the strategic importance of this financing, but the inherent dilution risk warrants a cautious approach.

Keywords

Actelis Networks, ELOC Purchase Agreement, White Lion Capital, Nasdaq Listing Rule 5635(d), common stock issuance, shareholder approval, dilution, capital raise, proxy statement, special meeting, equity line of credit

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.